| Market Capitalization (Millions $) |
2 |
| Shares
Outstanding (Millions) |
2 |
| Employees |
71 |
| Revenues (TTM) (Millions $) |
-1 |
| Net Income (TTM) (Millions $) |
-19 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Vaccinex Inc
Vaccinex Inc is a clinical-stage biotechnology company that focuses on the discovery and development of novel therapeutic antibodies for the treatment of cancer and neurodegenerative diseases. The company uses its proprietary antibody discovery platform, called ActivMAb, to identify and develop antibodies that can selectively target and neutralize specific disease-causing proteins.
Vaccinex has a particular expertise in the development of antibodies that target the CXCL13 chemokine, which is found in high levels in the tumor microenvironment in various cancers. By targeting CXCL13, Vaccinex aims to disrupt the tumor microenvironment and enhance the body's immune response to fight cancer.
In addition to its cancer programs, Vaccinex is also exploring the therapeutic potential of its antibodies in neurodegenerative diseases such as Huntington's disease and Alzheimer's disease. The company's pipeline includes several antibody candidates in various stages of preclinical and clinical development.
Vaccinex has ongoing collaborations with pharmaceutical companies and research institutions to further advance its antibody programs. The company's goal is to develop innovative antibody-based therapies that can improve patient outcomes and address significant unmet medical needs.
Company Address: 1895 Mount Hope Avenue Rochester 14620 NY
Company Phone Number: 271-2700 Stock Exchange / Ticker: NONE VCNX
|
